AIPPI World Congress
September 10 to 13, 2022
Location
San Francisco, California, USA
Contact
Credits
CLE available, total minutes TBD
Registration
AIPPI, hosted by the US Group of AIPPI, will be coming together in person
again to take part in the making of AIPPI's resolutions. Experts from
different countries and regions will be sharing and exchanging insights
on various areas of IP. 
Exceptional Programme:
- Panel Sessions (incl. Pharma Panels)
- UPC Boot Camp NEW
- AIPPI Cafés
- Women in AIPPI Social Event
- Young Members Forum
- 3 Social Events (incl. Closing Dinner)
IP Lunches (incl. Diversity and Inclusion Today, Would you like some IP with your Wine?, and Copyright in Graffiti and Street Art)
AIPPI offers an Exclusive Limited Package that includes hotel accommodation at an attractive fee.
The package is limited and will be offered on a first-come-first-served basis.
For more information, to view the Study Questions, and to learn about Sponsorship Opportunities: CLICK HERE
CLE will be offered, total amount to be determined.
If you're not currently a member of AIPPI, you can join and register directly through the registration process. If you're already an AIPLA member, but are not a member of AIPPI-US, you can join the group during the renewal process by adding AIPPI-US when you renew. If you're not an AIPLA member, you can join AIPLA and add AIPPI-US through the join process. For more information about membership eligibility please see the Committee webpage here: https://www.aipla.org/committees/aippi-us
News
-
AIPLA Comments on CNIPA Draft Measures for Prioritized Patent Examination
April 1, 2026
Arlington, VA. March 30, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the China National Intellectual Property Administration (CNIPA) regarding the Draft Measures for the Administration of Prioritized Examination of Patents. -
AIPLA Files Amicus Brief in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc
March 31, 2026
Arlington, VA. March 27, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus curiae brief with the Supreme Court in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889. AIPLA urges the Court to affirm the Federal Circuit’s application of the established Iqbal/Twombly pleading standard and inducement law in reviewing Hikma’s motion to dismiss Amarin’s claim that Hikma’s conduct, in combination with its “skinny label,” induced infringement of Amarin’s patented treatment methods. -
Supreme Court Issues Unanimous Decision in Cox Communications, Inc. v. Sony Music Entertainment
March 25, 2026
On March 25, 2026, the Supreme Court issued a unanimous decision in Cox Communications, Inc. v. Sony Music Entertainment. The majority opinion limits contributory liability to situations where a party intended that its service be used for infringement, either by affirmatively inducing infringement or by selling a service tailored to infringement. A concurring opinion by Justice Sotomayor argues that the material contribution test should be retained, and that other forms of secondary liability can be found, which is consistent with the position asserted by AIPLA in its amicus brief filed on September 5, 2025. To read the opinion of the Court, please click here. -
AIPLA Comments on the Draft Trademark Law of the People’s Republic of China
March 23, 2026
Arlington, VA. February 9, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the Legislative Affairs Commission of the Standing Committee of the National People’s Congress regarding the latest Draft Trademark Law of the People’s Republic of China. AIPLA recognized the NPC’s efforts to streamline trademark procedures, strengthen protection, and address abusive and bad-faith filing practices. -
AIPLA Files Amicus Brief in USAA v. PNC Bank
March 3, 2026
Arlington, VA. March 2, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief with the Supreme Court in USAA v. PNC Bank, N.A., No. 25-853, in support of USAA’s petition for certiorari, urging the Court to provide much-needed guidance to address the unpredictable and overly broad application of the judicial exceptions to patent-eligible subject matter under 35 U.S.C. § 101, particularly the “abstract idea” exception.
